Jang-Wook Sohn

Prof. Jang-Wook Sohn


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2013 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
SKSi-Hyun Kim
Si-Hyun Kim
YYYoung Kyung Yoon
Young Kyung Yoon
MKMin Ja Kim
Min Ja Kim
JSJang-Wook Sohn
Jang-Wook Sohn
The time to positivity (TTP) of blood cultures is associated with the microbial load in the blood and prognosis in patients with bloodstream infections caused by various bacterial species. However, relevant information about the TTP for Candida species in candidaemia is limited. We investigated the clinical impact of the TTP on mortality in patients with candidaemia. All consecutive patients ≥18 years of age with candidaemia between January 2006 and July 2012 were included. The demographics, clinical and microbiological characteristics, antifungal treatment and outcomes of the patients were collected retrospectively. A total of 152 patients were identified. The overall mortality rate at 6 weeks was 53%. The median TTP for Candida isolates was 27 h (IQR 19–37 h). A TTP of ≤24 h was significantly related to a higher mortality rate (P = 0.021). In a multivariate Cox regression analysis, the Charlson comorbidity index value [adjusted hazard ratio (HR) 1.15, 95% CI 1.02–1.29, P = 0.018], sequential organ failure assessment score (adjusted HR 1.23, 95% CI 1.13–1.34, P < 0.001), TTP ≤24 h (adjusted HR 2.74, 95% CI 1.51–4.97, P = 0.001), timing of appropriate antifungal therapy >72 h (adjusted HR 2.38, 95% CI 1.26–4.51, P = 0.008) and persistent candidaemia (adjusted HR 2.50, 95% CI 1.33–4.72, P = 0.005) were independently associated with the 6 week mortality rate. A short TTP (≤24 h) for Candida species was independently associated with increased mortality in patients with candidaemia. Additional studies on the relevance of the TTP to clinical outcome in patients with candidaemia are needed.

1 January 2023 in Infection & Chemotherapy
Verified
Journal Article
Open access
JKJeong Yeon Kim
Jeong Yeon Kim
JSJin Woong Suh
Jin Woong Suh
KJKang Jae-Seong
Kang Jae-Seong
SKSun Bean Kim
Sun Bean Kim
YYYoung Kyung Yoon
Young Kyung Yoon
JSJang-Wook Sohn
Jang-Wook Sohn
Kim JY, et al. Infect Chemother. 2023 Jan;55:e1. https://doi.org/10.3947/ic.2022.0145

1 January 2013 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
SKSi-Hyun Kim
Si-Hyun Kim
YYYoung Kyung Yoon
Young Kyung Yoon
MKM.J. Kim
M.J. Kim
JSJang-Wook Sohn
Jang-Wook Sohn
Mixed Candida/bacterial bloodstream infections (BSIs) have been reported to occur in more than 23% of all episodes of candidaemia. However, the clinical implications of mixed Candida/bacterial BSIs are not well known. We performed a retrospective case-control study of all consecutive patients with candidaemia over a 5-year period to determine the risk factors for and clinical outcomes of mixed Candida/bacterial BSIs (cases) compared with monomicrobial candidaemia (controls). Thirty-seven (29%) out of 126 patients with candidaemia met the criteria for cases. Coagulase-negative staphylococci were the predominant bacteria (23%) in cases. In multivariate analysis, duration of previous hospital stay >7 weeks (odds ratio (OR), 2.86; 95% confidence interval (CI), 1.09–7.53), prior antibiotic therapy ≥7 days (OR, 0.33; 95% CI, 0.14–0.82) and septic shock at the time of candidaemia (OR, 2.60; 95% CI, 1.14–5.93) were significantly associated with cases. Documented clearance of candidaemia within 3 days after initiation of antifungal therapy was less frequent in cases (63% vs. 84%; p = 0.035). The difference in the rate of treatment failure at 2 weeks was not significant between cases (68%) and controls (62%; p = 0.55). The crude mortality at 6 weeks and survival through 100 days did not differ between the two patient groups (p = 0.56 and p = 0.80, respectively). Mixed Candida/bacterial BSIs showed a lower clearance rate of candidaemia during the early period of antifungal therapy, although the treatment response and survival rate were similar regardless of concurrent bacteraemia. Further studies on the clinical relevance of species-specific Candida-bacterial interactions are needed.

4 May 2013 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
JSJoon Young Song
Joon Young Song
JCJun Yong Choi
Jun Yong Choi
JLJin-Soo Lee
Jin-Soo Lee
IBIn-Gyu Bae
In-Gyu Bae
YKYoung Keun Kim
Young Keun Kim
HCHee Jin Cheong
Hee Jin Cheong
Background: Streptococcus pneumoniae causes a broad spectrum of illnesses ranging from mild upper respiratory tract infections to invasive pneumococcal disease (IPD). Quantitative data on the burden of pneumococcal disease, important for the establishment of appropriate vaccination strategies, is currently lacking in adults. Methods: This multicenter, retrospective cohort study was designed to estimate the clinical and economic burden of IPD in adults over the last decade. Data were collected from patients with IPD at 10 university hospitals in South Korea. We estimated the proportion of IPD among all hospitalized patients, the case fatality rate, and the direct medical costs of IPD. Data were further analyzed according to age and risk groups. Results: During the study period, 970 patients with IPD were identified. The mean age for all patients was 60.9 years; patients aged 50–64 years (33.0%) were most numerous, followed by those aged 65–74 years (27.4%). Overall, the proportion of IPD was 0.36 cases/1000 hospitalized patients and the case fatality rate was 30.9%, which increased significantly with age (p < 0.01). The mean direct medical costs were estimated to be US $7,452 without a difference between age and risk groups. On multivariate analysis, old age, advanced ECOG performance status, bacteremic pneumonia, and nosocomial infection were independent risk factors of 30-day case fatality. Conclusions: The clinical disease burden of IPD increased significantly with age and direct medical costs from IPD were substantial, regardless of age and co-morbid conditions. The current age-based vaccination strategy appears to be appropriate.

15 July 2016 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
YYYoung Kyung Yoon
Young Kyung Yoon
DPDae Won Park
Dae Won Park
JSJang-Wook Sohn
Jang-Wook Sohn
HKHyo Youl Kim
Hyo Youl Kim
YKYeon-Sook Kim
Yeon-Sook Kim
MKMin Ja Kim
Min Ja Kim
The purported value of empirical therapy to cover methicillin-resistant Staphylococcus aureus (MRSA) has been debated for decades. The purpose of this study was to evaluate the effects of inappropriate empirical antibiotic therapy on clinical outcomes in patients with healthcare-associated MRSA bacteremia (HA-MRSAB). A prospective, multicenter, observational study was conducted in 15 teaching hospitals in the Republic of Korea from February 2010 to July 2011. The study subjects included adult patients with HA-MRSAB. Covariate adjustment using the propensity score was performed to control for bias in treatment assignment. The predictors of in-hospital mortality were determined by multivariate logistic regression analyses. In total, 345 patients with HA-MRSAB were analyzed. The overall in-hospital mortality rate was 33.0 %. Appropriate empirical antibiotic therapy was given to 154 (44.6 %) patients. The vancomycin minimum inhibitory concentrations of the MRSA isolates ranged from 0.5 to 2 mg/L by E-test. There was no significant difference in mortality between propensity-matched patient pairs receiving inappropriate or appropriate empirical antibiotics (odds ratio [OR] = 1.20; 95 % confidence interval [CI] = 0.71–2.03). Among patients with severe sepsis or septic shock, there was no significant difference in mortality between the treatment groups. In multivariate analyses, severe sepsis or septic shock (OR = 5.45; 95 % CI = 2.14–13.87), Charlson’s comorbidity index (per 1-point increment; OR = 1.52; 95 % CI = 1.27–1.83), and prior receipt of glycopeptides (OR = 3.24; 95 % CI = 1.08–9.67) were independent risk factors for mortality. Inappropriate empirical antibiotic therapy was not associated with clinical outcome in patients with HA-MRSAB. Prudent use of empirical glycopeptide therapy should be justified even in hospitals with high MRSA prevalence.

1 March 2021 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
HSHyeri Seok
Hyeri Seok
WCWon Suk Choi
Won Suk Choi
SLShinwon Lee
Shinwon Lee
CMChisook Moon
Chisook Moon
DPDae Won Park
Dae Won Park
JSJang-Wook Sohn
Jang-Wook Sohn
Objectives: The optimal treatment option for carbapenem-resistant Acinetobacter baumannii (CRAB) is still limited. This study investigated the efficacy of three or more antibiotic types and regimens for treatment of CRAB infection in high CRAB endemic areas. Methods: A multicentre retrospective study was conducted to evaluate the efficacy of treatment types and regimens of CRAB infections in 10 tertiary hospitals in the Republic of Korea. The outcomes comprised 7 day and 28-day mortality, and clinical and microbiological responses at 7 days, 28 days, and the end of treatment. Nephrotoxicity and hepatotoxicity were evaluated as drug adverse reactions. Results: A total of 282 patients were included in the study. Among the CRAB strains, the two most susceptible antibiotics were colistin (99.6%) and minocycline (80.4%). A combination of colistin and carbapenem significantly reduced 7-day mortality, and a sulbactam-containing regimen significantly reduced 28-day mortality. Colistin monotherapy was significantly associated with increased 7-day and 28-day mortality. A minocycline-containing regimen showed the best microbiological responses at 7 days, 28 days, and the end of treatment. Colistin and tigecycline were associated with increased nephrotoxicity and hepatotoxicity, respectively. Subgroup analysis of patients with pneumonia showed similar results to the overall CRAB infection. Conclusions: A combination of colistin and carbapenem and sulbactam-containing regimen may contribute improved mortality in CRAB infections. Colistin monotherapy should be considered cautiously in severe CRAB infections or CRAB pneumonia. A minocycline-containing regimen showed the best microbiological responses, and further studies may be needed to evaluate improved mortality. (c) 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/). Objectives: The optimal treatment option for carbapenem-resistant Acinetobacter baumannii (CRAB) is still limited. This study investigated the efficacy of three or more antibiotic types and regimens for treatment of CRAB infection in high CRAB endemic areas. Methods: A multicentre retrospective study was conducted to evaluate the efficacy of treatment types and regimens of CRAB infections in 10 tertiary hospitals in the Republic of Korea. The outcomes comprised 7day and 28-day mortality, and clinical and microbiological responses at 7 days, 28 days, and the end of treatment. Nephrotoxicity and hepatotoxicity were evaluated as drug adverse reactions. Results: A total of 282 patients were included in the study. Among the CRAB strains, the two most susceptible antibiotics were colistin (99.6%) and minocycline (80.4%). A combination of colistin and carbapenem significantly reduced 7-day mortality, and a sulbactam-containing regimen significantly reduced 28-day mortality. Colistin monotherapy was significantly associated with increased 7-day and 28-day mortality. A minocycline-containing regimen showed the best microbiological responses at 7 days, 28 days, and the end of treatment. Colistin and tigecycline were associated with increased nephrotoxicity and hepatotoxicity, respectively. Subgroup analysis of patients with pneumonia showed similar results to the overall CRAB infection. Conclusions: A combination of colistin and carbapenem and sulbactam-containing regimen may contribute improved mortality in CRAB infections. Colistin monotherapy should be considered cautiously in severe CRAB infections or CRAB pneumonia. A minocycline-containing regimen showed the best microbiological responses, and further studies may be needed to evaluate improved mortality. ? 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.